retatrutide clinical trials news VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide for weight loss: Study
Description
In this case, Orlistat might be a better option for you
Emotion Review, 3, 7482
As of the time of writing, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and no UK Summary of Product Characteristics (SmPC) exists for it
With headlines and social media amplifying new findings, counseling patients on GLP-1 therapies has become more complex
If you are in a clinical trial and not seeing expected results, several factors may explain this
:max_bytes(150000):strip_icc()/VWH-GettyImages-2247616008-f6337b6fe79748e9894463fef7b147d3.jpg)
